A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.
Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F.
Trachtman H, et al. Among authors: hard ml.
Kidney Int. 2011 Jun;79(11):1236-43. doi: 10.1038/ki.2011.33. Epub 2011 Mar 2.
Kidney Int. 2011.
PMID: 21368745
Free PMC article.
Clinical Trial.